PubMed

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J.

Ann Intern Med. 2006 Dec 19;145(12):913-23. Review.PMID: 17179059 [PubMed - indexed for MEDLINE]Related articlesFree article

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Maekawa T, Ashihara E, Kimura S.

Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. Review.PMID: 17929114 [PubMed - indexed for MEDLINE]Related articles

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

Kujawski L, Talpaz M.

Leuk Lymphoma. 2007 Dec;48(12):2310-22. Review.PMID: 18067005 [PubMed - indexed for MEDLINE]Related articles

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.PMID: 17317816 [PubMed - indexed for MEDLINE]Related articlesFree article

Overcoming kinase resistance in chronic myeloid leukemia.

Lee F, Fandi A, Voi M.

Int J Biochem Cell Biol. 2008;40(3):334-43. Review.PMID: 18401881 [PubMed - indexed for MEDLINE]Related articles

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Walz C, Sattler M.

Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. Epub 2005 Oct 5. Review.PMID: 16213151 [PubMed - indexed for MEDLINE]Related articles

New strategies in controlling drug resistance in chronic myeloid leukemia.

Frame D.

Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S16-21. Review.PMID: 18056927 [PubMed - indexed for MEDLINE]Related articles

Therapy options in imatinib failures.

Ramirez P, DiPersio JF.

Oncologist. 2008 Apr;13(4):424-34. Review.PMID: 18448557 [PubMed - indexed for MEDLINE]Related articlesFree article

Targeted drugs in chronic myeloid leukemia.

Gora-Tybor J, Robak T.

Curr Med Chem. 2008;15(29):3036-51. Review.PMID: 19075651 [PubMed - indexed for MEDLINE]Related articles

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. Review.PMID: 17970609 [PubMed - indexed for MEDLINE]Related articlesFree article

New strategies in controlling drug resistance.

Frame D.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):13-7. Review.PMID: 17970610 [PubMed - indexed for MEDLINE]Related articlesFree article

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.

von Bubnoff N, Peschel C, Duyster J.

Leukemia. 2003 May;17(5):829-38. Review.PMID: 12750693 [PubMed - indexed for MEDLINE]Related articles

New tyrosine kinase inhibitors in chronic myeloid leukemia.

Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.

Haematologica. 2005 Apr;90(4):534-41.PMID: 15820950 [PubMed - indexed for MEDLINE]Related articlesFree article

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P.

Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22.PMID: 17715389 [PubMed - indexed for MEDLINE]Related articlesFree article

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

Li S.

Leuk Lymphoma. 2008 Jan;49(1):19-26. Review.PMID: 18203007 [PubMed - indexed for MEDLINE]Related articlesFree article

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R.

Leukemia. 2002 Nov;16(11):2190-6.PMID: 12399961 [PubMed - indexed for MEDLINE]Related articlesFree article

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

Nardi V, Azam M, Daley GQ.

Curr Opin Hematol. 2004 Jan;11(1):35-43. Review.PMID: 14676625 [PubMed - indexed for MEDLINE]Related articles

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

Steinberg M.

Clin Ther. 2007 Nov;29(11):2289-308. Review.PMID: 18158072 [PubMed - indexed for MEDLINE]Related articles

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.

Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.

Clin Cancer Res. 2006 Oct 1;12(19):5869-78.PMID: 17020995 [PubMed - indexed for MEDLINE]Related articlesFree article

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.

Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM.

Cancer Res. 2008 Dec 1;68(23):9809-16.PMID: 19047160 [PubMed - indexed for MEDLINE]Related articles